| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05372887 Details | 2023-12-11 Interventional | 2 | 0 | Cyclobenzaprine PTSD | The study was stopped due to business reasons. - | |||
| NCT05201183 Details | 2023-12-11 Interventional | 1/2 | 0 | Fludarabine Hematologic Neo… Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Precursor Cell … Acute Lymphocyt… Acute Myeloid L… Chronic Myeloid… | insufficient staff and updates in standard practice have made it difficult to recruit
participants - | |||
| NCT04497870 Details | 2023-12-11 Interventional | 1 | 0 | Menthol Peppermint oil Abdominal Pain | This study was superseded by NCT03295747 - | |||
| NCT04455815 2020-002110-41 Details | 2023-12-11 Interventional | 2 | 34 | Camostat Gabexate COVID-19 Infections COVID-19 Infect… | Sponsor decision - | |||
| NCT03964051 2017-003627-30 Details | 2023-12-11 Interventional | 4 | 7 | Omalizumab Anaphylaxis Food Hypersensi… Food Allergy | Finished - | |||
| NCT01050218 Details | 2023-12-11 Interventional | 3 | 237 | Desvenlafaxine … Diabetic Neurop… Peripheral Nerv… Diabetic Neurop… | Business reasons - | |||
| NCT05193604 Details | 2023-12-08 Interventional | 1 | 29 | Gemcitabine Paclitaxel Carcinoma Pancreatic Neop… Pancreatic Carc… | Terminated due to the adjustment of sponsor's development strategies and pipeline. - | |||
| NCT04513067 Details | 2023-12-08 Interventional | 1 | 3 | Pembrolizumab Neoplasms Advanced Solid … | Due to business decision - | |||
| NCT04478266 2020-001824-33 Details | 2023-12-08 Interventional | 3 | 1068 | Goserelin Letrozole Palbociclib Breast Neoplasm… Breast Cancer | The study was terminated based on the review by an independent data monitoring committee of the
prespecified interim analysis of the Phase 3 AMEERA-5 efficacy data. No new safety signals were
observed. The study was terminated based on the review by an independent data monitoring committee of the prespecified interim analysis of the Phase 3 AMEERA-5 efficacy data. | |||
| NCT03954314 Details | 2023-12-08 Interventional | 3 | [5 Refs] | 3242 | Tranexamic Acid Blood Loss, Sur… Hemorrhage Postoperative H… Seizures Bleeding Surgical Blood … | Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have
finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment
into the trial. - | ||
| NCT05653427 Details | 2023-12-07 Interventional | 2 | 18 | Amivantamab-vmj… Carcinoma Carcinoma, Hepa… | N~15 subjects data analysis did not meet statistical consideration of ORR and study
primary/secondary objectives were not met. Enrollment was terminated for futility - | |||
| NCT05487040 Details | 2023-12-07 Interventional | 1 | 15 | Nirmatrelvir Ritonavir COVID-19 | Decision to terminate study was due to slow enrolment and FDA input that available data may be
enough for dosing recommendations for severe renal disease (subject to review by FDA). - | |||
| NCT03701763 2018-002918-12 Details | 2023-12-07 Interventional | 3 | 245 | Apremilast Psoriasis | PPSO-003 (20200056) is closing: - Last Subject Enrolled was 30-Dec-2021 - The Recruitment
Status has to be updated to Terminated. LSLV was achieved 27-Mar-2023 - | |||
| NCT05364099 Details | 2023-12-06 Interventional | 4 | 0 | Lidocaine Triamcinolone Shoulder Pain Spinal Cord Inj… Chronic Shoulde… | Unable to feasibly complete study. - | |||
| NCT03582033 Details | 2023-12-06 Interventional | 1 | 83 | Dexamethasone Pomalidomide Multiple Myelom… Neoplasms, Plas… | Study closed due to portfolio prioritization - | |||
| NCT02608268 2015-002354-12 Details | 2023-12-06 Interventional | 1/2 | 252 | Decitabine Spartalizumab Neoplasms Advanced Malign… | Business reasons - | |||
| NCT04894994 Details | 2023-12-05 Interventional | 2 | 6 | Ipilimumab Melanoma Advanced Melano… | Change in clinical landscape The study was terminated early due to changes in the treatment landscape of melanoma that have occurred since the initiation of the study, leading to small numbers of subjects analyzed. | |||
| NCT02649673 Details | 2023-12-05 Interventional | 1 | 34 | Topotecan Lung Neoplasms Small Cell Lung… Ovarian Cancer Small Cell Lung… | Clinical program was discontinued by Novartis - | |||
| NCT02642094 Details | 2023-12-05 Interventional | 2 | 58 | Sirolimus Breast Neoplasm… Cancer of Breas… | The study was terminated early according to the protocol due to efficacy. Our hypothesis was that a low dose and short term treatment with rapamycin in patients with early stage breast cancer would show significantly attenuation of mammary stem and progenitor cell activity and tumor progression biomarkers in a non-randomized study. | |||
| NCT01751425 Details | 2023-12-05 Interventional | 1 | 8 | Dasatinib Imatinib Mesyla… Janus Kinase In… Nilotinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Neoplasm, Resid… Philadelphia Ch… Chronic Myeloge… Chronic Myeloge… Minimal Residua… Philadelphia Ch… | Per PI Request. 2) No additional benefit was noted with the addition of Ruxolitinib. - |